Cargando…
Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is highly variable, ranging from slowly progressive adrenomyeloneuropathy to severe brain demyelination and inflammation (cerebral ALD, CALD) affecting males with childhood peak onset. Risk models integrating blood-based biomarkers to indicate CALD o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497986/ https://www.ncbi.nlm.nih.gov/pubmed/37683329 http://dx.doi.org/10.1016/j.ebiom.2023.104781 |
_version_ | 1785105423320219648 |
---|---|
author | Weinhofer, Isabelle Rommer, Paulus Gleiss, Andreas Ponleitner, Markus Zierfuss, Bettina Waidhofer-Söllner, Petra Fourcade, Stéphane Grabmeier-Pfistershammer, Katharina Reinert, Marie-Christine Göpfert, Jens Heine, Anne Yska, Hemmo A.F. Casasnovas, Carlos Cantarín, Verónica Bergner, Caroline G. Mallack, Eric Forss-Petter, Sonja Aubourg, Patrick Bley, Annette Engelen, Marc Eichler, Florian Lund, Troy C. Pujol, Aurora Köhler, Wolfgang Kühl, Jörn-Sven Berger, Johannes |
author_facet | Weinhofer, Isabelle Rommer, Paulus Gleiss, Andreas Ponleitner, Markus Zierfuss, Bettina Waidhofer-Söllner, Petra Fourcade, Stéphane Grabmeier-Pfistershammer, Katharina Reinert, Marie-Christine Göpfert, Jens Heine, Anne Yska, Hemmo A.F. Casasnovas, Carlos Cantarín, Verónica Bergner, Caroline G. Mallack, Eric Forss-Petter, Sonja Aubourg, Patrick Bley, Annette Engelen, Marc Eichler, Florian Lund, Troy C. Pujol, Aurora Köhler, Wolfgang Kühl, Jörn-Sven Berger, Johannes |
author_sort | Weinhofer, Isabelle |
collection | PubMed |
description | BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is highly variable, ranging from slowly progressive adrenomyeloneuropathy to severe brain demyelination and inflammation (cerebral ALD, CALD) affecting males with childhood peak onset. Risk models integrating blood-based biomarkers to indicate CALD onset, enabling timely interventions, are lacking. Therefore, we evaluated the prognostic value of blood biomarkers in addition to current neuroimaging predictors for early detection of CALD. METHODS: We measured blood biomarkers in a retrospective, male CALD risk-assessment cohort consisting of 134 X-ALD patients and 66 controls and in a phenotype-blinded validation set (25 X-ALD boys, 4–13 years) using Simoa®and Luminex® technologies. FINDINGS: Among 25 biomarkers indicating axonal damage, astrocye/microglia activation, or immune-cell recruitment, neurofilament light chain (NfL) had the highest prognostic value for early indication of childhood/adolescent CALD. A plasma NfL cut-off level of 8.33 pg/mL, determined in the assessment cohort, correctly discriminated CALD with an accuracy of 96% [95% CI: 80–100] in the validation group. Multivariable logistic regression models revealed that combining NfL with GFAP or cytokines/chemokines (IL-15, IL-12p40, CXCL8, CCL11, CCL22, and IL-4) that were significantly elevated in CALD vs healthy controls had no additional benefit for detecting neuroinflammation. Some cytokines/chemokines were elevated only in childhood/adolescent CALD and already upregulated in asymptomatic X-ALD children (IL-15, IL-12p40, and CCL7). In adults, NfL levels distinguished CALD but were lower than in childhood/adolescent CALD patients with similar (MRI) lesion severity. Blood GFAP did not differentiate CALD from non-inflammatory X-ALD. INTERPRETATION: Biomarker-based risk prediction with a plasma NfL cut-off value of 8.33 pg/mL, determined by ROC analysis, indicates CALD onset with high sensitivity and specificity in childhood X-ALD patients. A specific pro-inflammatory cytokine/chemokine profile in asymptomatic X-ALD boys may indicate a primed, immanent inflammatory state aligning with peak onset of CALD. Age-related differences in biomarker levels in adult vs childhood CALD patients warrants caution in predicting onset and progression of CALD in adults. Further evaluations are needed to assess clinical utility of the NfL cut-off for risk prognosis of CALD onset. FUNDING: 10.13039/501100002428Austrian Science Fund, 10.13039/501100008731European Leukodystrophy Association. |
format | Online Article Text |
id | pubmed-10497986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104979862023-09-14 Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy Weinhofer, Isabelle Rommer, Paulus Gleiss, Andreas Ponleitner, Markus Zierfuss, Bettina Waidhofer-Söllner, Petra Fourcade, Stéphane Grabmeier-Pfistershammer, Katharina Reinert, Marie-Christine Göpfert, Jens Heine, Anne Yska, Hemmo A.F. Casasnovas, Carlos Cantarín, Verónica Bergner, Caroline G. Mallack, Eric Forss-Petter, Sonja Aubourg, Patrick Bley, Annette Engelen, Marc Eichler, Florian Lund, Troy C. Pujol, Aurora Köhler, Wolfgang Kühl, Jörn-Sven Berger, Johannes eBioMedicine Articles BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is highly variable, ranging from slowly progressive adrenomyeloneuropathy to severe brain demyelination and inflammation (cerebral ALD, CALD) affecting males with childhood peak onset. Risk models integrating blood-based biomarkers to indicate CALD onset, enabling timely interventions, are lacking. Therefore, we evaluated the prognostic value of blood biomarkers in addition to current neuroimaging predictors for early detection of CALD. METHODS: We measured blood biomarkers in a retrospective, male CALD risk-assessment cohort consisting of 134 X-ALD patients and 66 controls and in a phenotype-blinded validation set (25 X-ALD boys, 4–13 years) using Simoa®and Luminex® technologies. FINDINGS: Among 25 biomarkers indicating axonal damage, astrocye/microglia activation, or immune-cell recruitment, neurofilament light chain (NfL) had the highest prognostic value for early indication of childhood/adolescent CALD. A plasma NfL cut-off level of 8.33 pg/mL, determined in the assessment cohort, correctly discriminated CALD with an accuracy of 96% [95% CI: 80–100] in the validation group. Multivariable logistic regression models revealed that combining NfL with GFAP or cytokines/chemokines (IL-15, IL-12p40, CXCL8, CCL11, CCL22, and IL-4) that were significantly elevated in CALD vs healthy controls had no additional benefit for detecting neuroinflammation. Some cytokines/chemokines were elevated only in childhood/adolescent CALD and already upregulated in asymptomatic X-ALD children (IL-15, IL-12p40, and CCL7). In adults, NfL levels distinguished CALD but were lower than in childhood/adolescent CALD patients with similar (MRI) lesion severity. Blood GFAP did not differentiate CALD from non-inflammatory X-ALD. INTERPRETATION: Biomarker-based risk prediction with a plasma NfL cut-off value of 8.33 pg/mL, determined by ROC analysis, indicates CALD onset with high sensitivity and specificity in childhood X-ALD patients. A specific pro-inflammatory cytokine/chemokine profile in asymptomatic X-ALD boys may indicate a primed, immanent inflammatory state aligning with peak onset of CALD. Age-related differences in biomarker levels in adult vs childhood CALD patients warrants caution in predicting onset and progression of CALD in adults. Further evaluations are needed to assess clinical utility of the NfL cut-off for risk prognosis of CALD onset. FUNDING: 10.13039/501100002428Austrian Science Fund, 10.13039/501100008731European Leukodystrophy Association. Elsevier 2023-09-07 /pmc/articles/PMC10497986/ /pubmed/37683329 http://dx.doi.org/10.1016/j.ebiom.2023.104781 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Weinhofer, Isabelle Rommer, Paulus Gleiss, Andreas Ponleitner, Markus Zierfuss, Bettina Waidhofer-Söllner, Petra Fourcade, Stéphane Grabmeier-Pfistershammer, Katharina Reinert, Marie-Christine Göpfert, Jens Heine, Anne Yska, Hemmo A.F. Casasnovas, Carlos Cantarín, Verónica Bergner, Caroline G. Mallack, Eric Forss-Petter, Sonja Aubourg, Patrick Bley, Annette Engelen, Marc Eichler, Florian Lund, Troy C. Pujol, Aurora Köhler, Wolfgang Kühl, Jörn-Sven Berger, Johannes Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy |
title | Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy |
title_full | Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy |
title_fullStr | Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy |
title_full_unstemmed | Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy |
title_short | Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy |
title_sort | biomarker-based risk prediction for the onset of neuroinflammation in x-linked adrenoleukodystrophy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497986/ https://www.ncbi.nlm.nih.gov/pubmed/37683329 http://dx.doi.org/10.1016/j.ebiom.2023.104781 |
work_keys_str_mv | AT weinhoferisabelle biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT rommerpaulus biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT gleissandreas biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT ponleitnermarkus biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT zierfussbettina biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT waidhofersollnerpetra biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT fourcadestephane biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT grabmeierpfistershammerkatharina biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT reinertmariechristine biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT gopfertjens biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT heineanne biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT yskahemmoaf biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT casasnovascarlos biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT cantarinveronica biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT bergnercarolineg biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT mallackeric biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT forsspettersonja biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT aubourgpatrick biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT bleyannette biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT engelenmarc biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT eichlerflorian biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT lundtroyc biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT pujolaurora biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT kohlerwolfgang biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT kuhljornsven biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy AT bergerjohannes biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy |